IQVIA Holdings Inc (IQV)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at IQVIA Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 235.00 $ — 86% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 16.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 23
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12.96 | 12.87 – 13.38 | 17,413 | 8.7% | 21 |
| 12/31/2027 | 14.43 | 13.90 – 15.48 | 18,463 | 11.4% | 21 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 2.42 | -5.00 | 3,958 | 2.30 | 11.00 | 885 | 721 |
| 2025: Q1 | 1.40 | -10.20 | 3,829 | 2.50 | 6.50 | 568 | 426 |
| 2025: Q2 | 1.54 | -22.00 | 4,017 | 5.30 | 6.60 | 443 | 292 |
| 2025: Q3 | 1.93 | 24.60 | 4,100 | 5.20 | 8.10 | 908 | 1,201 |
| 2025: Q4 | 2.99 | 23.70 | 4,364 | 10.30 | 11.80 | 735 | 561 |
| 2026: Q1 | 1.61 | 15.00 | 4,151 | 8.40 | 6.60 | 618 | 491 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 6,815 | 642 | 115 | 0.76 | 860 | 8,633 | 21,208 |
| 2017 | 9,702 | 719 | 1,309 | 5.88 | 970 | 8,109 | 22,742 |
| 2018 | 10,412 | 741 | 259 | 1.24 | 1,254 | 6,714 | 22,549 |
| 2019 | 11,088 | 777 | 191 | 0.96 | 1,417 | 6,003 | 23,251 |
| 2020 | 11,359 | 731 | 279 | 1.43 | 1,959 | 6,001 | 24,564 |
| 2021 | 13,874 | 1,393 | 966 | 4.95 | 2,942 | 6,042 | 24,689 |
| 2022 | 14,410 | 1,799 | 1,091 | 5.72 | 2,260 | 5,765 | 25,337 |
| 2023 | 14,984 | 1,977 | 1,358 | 7.29 | 2,149 | 6,112 | 26,681 |
| 2024 | 15,405 | 2,202 | 1,373 | 7.49 | 2,716 | 6,067 | 26,899 |
| 2025 | 16,310 | 2,287 | 1,360 | 7.84 | 2,654 | 6,503 | 29,944 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
IQVIA Holdings Inc. bietet klinische Forschungsdienste, kommerzielle Insights und Gesundheitsintelligenz für die Life-Sciences- und Gesundheitsbranche in Nord- und Südamerika, Europa, Afrika und dem asiatisch-pazifischen Raum an.
| Employees | 94,000 |
|---|---|
| Headquarters | Durham, NC |
| Address | 2400 Ellis Road, 27703 Durham, United States |
| Phone | 919 998 2000 |
| Website | iqvia.com |
| IPO Date | 9. May 2013 |
| ISIN | US46266C1053 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ari Bousbib | CEO & Chairman | 1961 |
| Eric M. Sherbet J.D. | Executive VP, General Counsel & Secretary | 1964 |
| W. Richard Staub III | President of Research & Development Solutions | 1963 |
| Alistair Grenfell | President of Commercial Solutions | 1974 |
| Michael J. Fedock MBA | Executive VP & Chief Financial Officer | 1976 |
| James G. Berkshire | Executive Vice President of Global Infrastructure & Operations | 1974 |
| Keriann Cherofsky | Senior VP, Corporate Controller & Chief Accounting Officer | 1985 |
| Jeffrey A. Spaeder M.D. | Chief Medical & Scientific Officer | – |
| Kerri Joseph | Senior VP of Investor Relations & Treasurer | – |
| Duane Sachs | Senior Vice President of Corporate Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Sherbet Eric | See Remarks | Sell | 5,000 | 249.16 | 1,245,800 |
| 29. Jul 2026 | Cherofsky Keriann | See Remarks | Sell | 558 | 245.21 | 136,827 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Other | 2,069 | 247.00 | 511,043 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Other | 47,858 | 244.60 | 11,706,067 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Sell | 53,191 | 244.78 | 13,020,093 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Sell | 44,039 | 246.08 | 10,837,117 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Sell | 4,584 | 246.85 | 1,131,560 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Sell | 4,465 | 247.10 | 1,103,302 |
| 29. Jul 2026 | Bousbib Ari | See Remarks | Other | 156,206 | 78.21 | 12,216,871 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.